Morgan Stanley raised the firm’s price target on Hologic (HOLX) to $69 from $65 and keeps an Equal Weight rating on the shares following “solid” revenue and EPS beats for the quarter along with FY25 guidance being raised for the Q3 beat, foreign exchange and M&A contribution.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic’s Hold Rating: Balancing Molecular Diagnostics Growth with Breast Health Challenges and External Headwinds
- Hologic’s Earnings Call: Strong Q3 Performance and Optimism
- Hologic price target raised to $75 from $70 at Mizuho
- Hologic’s Mixed Financial Outlook: Hold Rating Amid Growth Concerns and Margin Declines
- Hologic’s Growth Potential: Strong Q3 Results and Positive Outlook Justify Buy Rating